Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis (AnnIE)
Primary Purpose
Endocarditis, Thrombosis
Status
Terminated
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
99mTc-Annexin V-128 SPECT
Sponsored by
About this trial
This is an interventional diagnostic trial for Endocarditis focused on measuring Radionuclide imaging, Annexin
Eligibility Criteria
Inclusion Criteria:
- stable clinical status
- signed informed consent
contraception in women of childhood potential
- Endocarditis group:
definite ou possible endocarditis (modified Duke criteria)
- Atrial thrombosis group:
- presence of atrial thrombosis evidenced by transesophageal echocardiography
Exclusion Criteria:
- pregnant or lactating women
contra-indication to both MRI and CT
- Endocarditis group:
- history of cardiac surgery in relation with the current episode
- (effective) antibiotic regimen for more than 15 days
Sites / Locations
- Bichat Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Imaging
Arm Description
99mTc Annexin V-128 SPECT
Outcomes
Primary Outcome Measures
Diagnostic sensitivity in infective endocarditis and atrial thrombus
Secondary Outcome Measures
Diagnostic value (sensitivity and specificity) in infective endocarditis
Diagnostic sensitivity in atrial thrombus
Full Information
NCT ID
NCT02459613
First Posted
May 13, 2015
Last Updated
August 25, 2021
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators
Advanced Accelerator Applications
1. Study Identification
Unique Protocol Identification Number
NCT02459613
Brief Title
Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
Acronym
AnnIE
Official Title
Evaluation de la rhAnnexine V-128 radiomarquée Dans le Diagnostic de l'Endocardite Infectieuse, du Thrombus Atrial et de Leurs Complications Emboliques associées
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Terminated
Study Start Date
February 5, 2016 (Actual)
Primary Completion Date
May 2017 (Actual)
Study Completion Date
May 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators
Advanced Accelerator Applications
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Intraluminal thrombi adherent to cardiac valves or atria share a common pathophysiology involving the aggregation of activated platelets with phosphatidylserine (PS) expression on the outer layer of the thrombus. They also share common complications, i.e. damages to the underlying myocardium and embolic risk related to thrombus fragmentation. The diagnostic work-up, currently relying on morphologic imaging alone (mainly echography), lacks sensitivity and does not allow to differentiate between active (renewal and growth activity) and quiescent (scarred) thrombus. It is therefore highly desirable to develop a new approach able to non-invasively provide insight on the biological activity of thrombi and to detect embolic events in a single exam.
Annexin V is a 36 kDa endogenous glycoprotein which binds PS with nanomolar affinity. Radiolabeled Annexin V has been shown to provide molecular imaging of PS expressed by apoptotic cells or activated platelets. The ability of the imaging agent to bind mural thrombus has been established in vivo in a murine model of abdominal aortic aneurysm and ex vivo in human. It has been also shown that radiolabeled Annexin V allowed in vivo detection of vegetations and secondary pulmonary emboli with high sensitivity in various animal models of infective endocarditis.
A radiolabeling kit of annexin V complying with GMP requirements has been developed (rhAnnexine V-128, Advanced Accelerator Applications - Atreus) and is currently available. AnniE is a single centre, proof of concept, interventional, open, non-randomized study aiming at evaluating the sensitivity of 99mTc-Annexin V-128 in the detection thrombus in comparison with reference imaging in patients presenting with either: 1/ infective endocarditis or 2/ atrial thrombus. The safety of the 99mTc-Annexin V-128 will be assessed in a first phase (10 first patients enrolled). Data in relation with safety of the imaging agent will be reviewed by an independent Data and Safety Monitoring Board (DSMB); in case of positive answer, the study will continue with a second phase. The data gathered in all patients (n=120) will be used to determine outcome measures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endocarditis, Thrombosis
Keywords
Radionuclide imaging, Annexin
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Imaging
Arm Type
Experimental
Arm Description
99mTc Annexin V-128 SPECT
Intervention Type
Drug
Intervention Name(s)
99mTc-Annexin V-128 SPECT
Primary Outcome Measure Information:
Title
Diagnostic sensitivity in infective endocarditis and atrial thrombus
Time Frame
up to 4 weeks
Secondary Outcome Measure Information:
Title
Diagnostic value (sensitivity and specificity) in infective endocarditis
Time Frame
up to 4 weeks
Title
Diagnostic sensitivity in atrial thrombus
Time Frame
up to 4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
stable clinical status
signed informed consent
contraception in women of childhood potential
Endocarditis group:
definite ou possible endocarditis (modified Duke criteria)
Atrial thrombosis group:
presence of atrial thrombosis evidenced by transesophageal echocardiography
Exclusion Criteria:
pregnant or lactating women
contra-indication to both MRI and CT
Endocarditis group:
history of cardiac surgery in relation with the current episode
(effective) antibiotic regimen for more than 15 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominique Le Guludec, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bichat Hospital
City
Paris
ZIP/Postal Code
75018
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
25431156
Citation
Benali K, Louedec L, Azzouna RB, Merceron O, Nassar P, Al Shoukr F, Petiet A, Barbato D, Michel JB, Sarda-Mantel L, Le Guludec D, Rouzet F. Preclinical validation of 99mTc-annexin A5-128 in experimental autoimmune myocarditis and infective endocarditis: comparison with 99mTc-HYNIC-annexin A5. Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00049.
Results Reference
background
PubMed Identifier
18227388
Citation
Rouzet F, Dominguez Hernandez M, Hervatin F, Sarda-Mantel L, Lefort A, Duval X, Louedec L, Fantin B, Le Guludec D, Michel JB. Technetium 99m-labeled annexin V scintigraphy of platelet activation in vegetations of experimental endocarditis. Circulation. 2008 Feb 12;117(6):781-9. doi: 10.1161/CIRCULATIONAHA.107.718114. Epub 2008 Jan 28.
Results Reference
background
PubMed Identifier
20404380
Citation
Duval X, Iung B, Klein I, Brochet E, Thabut G, Arnoult F, Lepage L, Laissy JP, Wolff M, Leport C; IMAGE (Resonance Magnetic Imaging at the Acute Phase of Endocarditis) Study Group. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann Intern Med. 2010 Apr 20;152(8):497-504, W175. doi: 10.7326/0003-4819-152-8-201004200-00006.
Results Reference
background
PubMed Identifier
16857952
Citation
Sarda-Mantel L, Coutard M, Rouzet F, Raguin O, Vrigneaud JM, Hervatin F, Martet G, Touat Z, Merlet P, Le Guludec D, Michel JB. 99mTc-annexin-V functional imaging of luminal thrombus activity in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2153-9. doi: 10.1161/01.ATV.0000237605.25666.13. Epub 2006 Jul 20.
Results Reference
background
Learn more about this trial
Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
We'll reach out to this number within 24 hrs